Abstract
OBJECTIVE:There are no doubts about the clinical benefits of treatment with GnRH analogs for patients diagnosed with central precocious puberty (CPP). However, laboratory monitoring of CPP is still a matter of considerable controversy in the literature. Therefore, the main objective of this study was to evaluate the cut-off values of stimulated LH that determine gonadotrophic suppression.METHODS:Twenty-four girls, on treatment with leuprorelin acetate (LA) at 3.75 mg IM every 28 days, were studied. The clinical parameters used to indicate clinical effectiveness were regression or maintenance of sexual characteristics according to the Tanner stage, growth velocity reduction, reduction or maintenance of the difference between bone age and chronological age and maintenance or improvement of the final height prediction. For the laboratory effectiveness test, basal estradiol, LH, and FSH levels were collected before and 1 and 2 h after the administration of 3.75 mg LA.RESULTS:Eleven girls showed improvement in all clinical parameters, and their effectiveness tests were compared to those of the other patients to calculate the cut-off values, which were ≤3.64 IU/L (p=0.004*) for LH after 1 h and ≤6.10 IU/L (p<0.001*) for LH after 2 h.CONCLUSION:The LH response after the LA stimulation test, associated with clinical data and within a context of CPP, constitutes a reliable and feasible resource and can assist in monitoring the effectiveness of treatment.
Highlights
Precocious puberty (PP) is classically defined as the development of secondary sexual characteristics before eight years of age in girls and before nine years of age in boys [1,2]
The inclusion criteria were girls with clinical aspects of Central precocious puberty (CPP), whose diagnosis was confirmed by the classic GnRH stimulation test or by a GnRHa test and who would be treated with depot GnRH analogs, intramuscularly, administered every 28 days [19,20,21,22,23]
There are no doubts regarding the need for CPP treatment with GnRHa and its clinical effectiveness [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20]
Summary
Precocious puberty (PP) is classically defined as the development of secondary sexual characteristics before eight years of age in girls and before nine years of age in boys [1,2]. The current treatment of choice for CPP consists of the administration of depot GnRH analogs (GnRHa). Received for publication on February 11, 2019. Accepted for publication on August 26, 2019
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
